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Abstract
Background: The Age-related Macular Degeneration Alliance International commissioned a
review of the literature on quality of life (QoL) in macular degeneration (MD) with a view to
increasing awareness of MD, reducing its impact and improving services for people with MD
worldwide.
Method: A systematic review was conducted using electronic databases, conference proceedings
and key journal hand search checks. The resulting 'White Paper' was posted on the AMD Alliance
website and is reproduced here.
Review: MD is a chronic, largely untreatable eye condition which leads to loss of central vision
needed for tasks such as reading, watching TV, driving, recognising faces. It is the most common
cause of blindness in the Western world. Shock of diagnosis, coupled with lack of information and
support are a common experience. Incidence of depression is twice that found in the community-
dwelling elderly, fuelled by functional decline and loss of leisure activities. Some people feel suicidal.
MD threatens independence, especially when comorbidity exacerbates functional limitations.
Rehabilitation, including low vision aid (LVA) provision and training, peer support and education,
can improve functional and psychological outcomes but many people do not receive services likely
to benefit them. Medical treatments, suitable for only a small minority of people with MD, can
improve vision but most limit progress of MD, at least for a time, rather than cure. The White
Paper considers difficulties associated with inappropriate use of health status measures and
misinterpretation of utility values as QoL measures: evidence suggests they have poor validity in
MD.
Conclusion: There is considerable evidence for the major damage done to QoL by MD which is
underestimated by health status and utility measures. Medical treatments are limited to a small
proportion of people. However, much can be done to improve QoL by early diagnosis of MD with
good communication of prognosis and continuing support. Support could include provision of
LVAs, peer support, education and effective help in adjusting to MD. It is vital that appropriate
measures of visual function and QoL be used in building a sound evidence base for the effectiveness
of rehabilitation and treatment.
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Age-related macular degeneration (MD) is a chronic, pro-
gressive eye disorder that mainly affects people over the
age of 50. It is the leading cause of blindness in the West-
ern world in people over 60 yrs [1] and the third most
common cause globally after cataract and glaucoma [1].
Data collated in 2002 indicated that MD was the cause of
8.7% of the global estimate of 161 million cases of visual
impairment [2]. Recently it was estimated that, in the UK,
with a population of 59 million [3], approximately
417,000 people have some degree of MD, of whom
214,000 have sufficient visual impairment for registration
as partially sighted or blind [4]. Now that people are liv-
ing longer the prevalence of MD is likely to increase [4].
MD leads to loss of central vision needed for activities
requiring fine vision such as reading, driving and recog-
nising faces. Peripheral vision is usually retained but MD
can impair proficiency in performing most activities in
daily living and can make it more difficult for people to
live independent lives.
There are two types of MD. Dry MD (also called atrophic
MD) accounts for about 80% of cases and generally devel-
ops slowly, often affecting both eyes simultaneously. It
usually, but not always, causes only mild loss of vision.
Dry MD is characterised by fatty deposits behind the ret-
ina which cause the macula to thin and dry out. Wet MD
(also called neovascular MD) is associated with rapidly
deteriorating vision and severe impairment and accounts
for 90% of cases of severe visual impairment due to MD.
Wet MD is caused by the growth of new blood vessels (a
process known as choroidal neovascularisation (CNV))
behind the retina. These new blood vessels are weak and
have a propensity to leak, damaging the retinal cells and
leading to scar tissue. There are subtypes of wet MD,
known as 'classic' and 'occult'. In classic CNV, the new
blood vessels can be seen distinctly by an ophthalmolo-
gist using angiography. In occult CNV, the leaking vessels
are obscured. Patients may present with a combination of
both occult and classic CNV.
MD is a largely untreatable condition. Treatment is appro-
priate for a small percentage of people if they are diag-
nosed at an early stage with particular types of the wet
form of the disease. Even then the treatment does not cure
the condition but can limit its progress, at least for a time
[5]. However, potential new treatments and rehabilitation
interventions are continually being developed and tested.
This report critically reviews the literature that relates to
the effects of MD on quality of life (QoL), and identifies
strategies most likely to improve QoL for the many people
who live with MD.
2. Measuring quality of life in MD
Although a great deal of QoL research is carried out there
is little agreement about the definition of QoL. The one
we prefer is based on the work of Joyce [6] and McGee and
colleagues [7]:
"Quality of life is how good or bad you feel your life to
be." [8]
Implicit in this definition is that QoL is a subjective per-
ception and that QoL means different things to different
people. Although many so-called quality of life measures
allow people to indicate their own perceived levels of
whatever aspect of life is being measured, many do not
allow individuals to report the relevance or importance of
that aspect of life for them [9-12]. Table 1 details the dif-
ferent measures referred to in this report that have been
used to measure QoL and other patient reported out-
comes (PROs) in research into MD.
2.1 Measuring Patient Reported Outcomes (PROs) in eye 
disease
2.1.1 Psychological well-being measures
These measure mood. People who feel depressed and anx-
ious are unlikely to describe their QoL as good. However,
even those who are not depressed or anxious may still feel
that their QoL is severely damaged by MD. Some well-
being scales, such as the Hospital Anxiety and Depression
Scale (HADS) [13] measure only negative well-being
(anxiety and depression). Where people have no anxiety
or depression to begin with, such a measure could show
no improvement. Measures which also investigate posi-
tive well-being (e.g. the well-being scales within the SF-36
measure vitality [14]) and particularly those which meas-
ure positive well-being with items concerned with enthu-
siasm for life (e.g. the Well-being Questionnaire (W-
BQ12) which measures energy and positive well-being as
well as anxiety and depression [15]) are more likely to
detect improvement in psychological well-being.
2.1.2 Health status (HS) measures
These investigate subjective perceptions of health but
unfortunately HS measures are often wrongly called QoL
measures and this has caused great confusion and mis-
leading conclusions [11]. HS is not QoL, although poor
HS may be associated with impaired QoL. Good HS does
not indicate that QoL is good. HS measures are rarely any
use as indicators of the impact of eye conditions on QoL
because most of the domains investigated are not affected
by visual impairment (e.g. pain, energy, appetite). For
example, the SF-36 [14], a generic HS measure, and the
shorter subset, SF-12, have been found to be sensitive to
age-related eye disease including MD in some work [16]
but not in most studies [17-21] and found to be only min-
imally responsive to change in visual acuity (VA) inPage 2 of 20
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Measure Country of
origin
Actually measures Validated for MD or
closest population
HS LS FS VF WB QoL
Hospital Anxiety and Depression Scale (HADS) [13] Denmark √ elderly
SF-36 [14] USA √ √* elderly
W-BQ12 [15] UK √* MD
HUI-3 [25] Canada √ √ community
EQ5D (EuroQol) [27] Europe √ √ community
Instrumental Activities of Daily Living scale (IADL) [30] USA √ MD
Sickness Impact Profile (SIP) [31] UK √ √ Elderly
Sickness Impact Profile for vision (SIPv) [32] UK √ √ Retinal disease
Activities of Daily Vision Scale (ADVS) [33] USA √ MD
14-item Vision Function Questionnaire (VF-14) [34] USA √ MD
Daily Living Tasks Dependent on Vision (DLTV) [36] UK √ MD, cataract
Low vision QoL (LVQOL) [37] UK √ √ mixed sample 
including MD
National Eye Institute Vision Function Questionnaire (NEI-VFQ25, 39, 
51) [38]
USA √ √ MD
Measure of the Impact of MD on QoL (MacDQoL) [42, 44] UK √ MD
Profile of Mood States (POMS) [65] USA √* elderly
Quality of Well-being Scale (QWB) [66] USA √ elderly
Diagnostic and statistical manual (DSMIV) [69] USA √ adults
Functional Vision Screening Questionnaire (FVSQ) [71] USA √ Vision impaired
Community Disability Scale (CDS) [72] USA √ adults
Life Satisfaction Index – Wellbeing [87] UK √ elderly
General Health Questionnaire [110] UK √* elderly
Positive and Negative Affect Scale [131] USA √* adults
Vision-related QoL (VQOL) [117] UK √ √ Vision impaired
Manchester Low Vision Questionnaire (MLVQ) [118] UK √ MD
Geriatric Depression Scale [115] UK √ elderly
Psychological General Well-being Index (PGWB) [123] USA √* adults
Multilevel Assessment Instrument (MAI) [132] USA √ elderly
Freiburg Inventory on Coping with Illness [133] Germany coping adults
* indicates that both negative and positive well-being are measured
patients with CNV, over a period of 2 years [22]. It was not
responsive to the impact of low vision services [23]. The
SF-12 was also found not to be responsive to change [24].
The health utility index (HUI-3) [25] includes items con-
cerned with vision and, unsurprisingly, proved more sen-
sitive to vision impairment [26] than the SF-12 and the
EQ5D [27] which investigates only five dimensions of
health, none of which is vision. This disappointing per-
formance of widely used HS measures in detailing impair-
ment in people with MD and other eye conditions can be
understood when it is appreciated that, for the most part,
the general population do not think of problems with
their eyesight when asked about their health. Patients
maybe registered blind with MD and still report that their
health is excellent. If asked about their QoL they may nev-
ertheless say it is shot to pieces by their MD. Quality of
health is quite a different matter from quality of life [11]
and this is particularly true for people with eye conditions,
including people with MD. When the SF-36 or EQ5D
show no impact of MD and are also wrongly referred to as
QoL measures it may be mistakenly concluded that MD
has no perceived impact on QoL when all that has been
shown is that MD has no perceived impact on health. The
literature on MD abounds with studies that have used
health status measures and wrongly referred to these as
QoL measures (e.g. [21,24,28,29]). It is essential that we
recognise this problem and are not misled by the data.
2.1.3 Functional status (FS) measures
These questionnaires investigate respondents' ability to
carry out activities of daily living (ADL) such as self-care
and eating. They do not specifically investigate vision-
related activities (e.g. reading, watching TV), although
they may contain some items that are relevant to vision.
Often they do not include psychological domains such as
confidence or worry. They do not necessarily correlate
well with objective measures of vision or with QoL
because FS measures only ask what a person can do, not
whether they want or need to do those things or how
important they are to their QoL. Nevertheless, using thePage 3 of 20
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designed for the study, Williams et al [30] demonstrated
that, compared to visually unimpaired elderly people,
patients with MD were 8 times more likely to report diffi-
culty shopping, 13 times more likely to have difficulty
managing finances, 4 times more likely to experience dif-
ficulties preparing meals, 12 times more likely to have
problems using a telephone, and 9 times more likely to
experience problems with light housework. The Sickness
Impact Profile (SIP) [31] is a measure of health-related
disability. A vision-related version of the scale (SIPV) [32]
was developed in which, for each question from the SIP
answered affirmatively, indicating dysfunction, a subse-
quent question asks if visual dysfunction contributes to
the reported difficulty. An American study of 86 retinal
patients (not elderly) found that SIPV scores showed
increased disability across mild, moderate and severe vis-
ual impairment and all but one of the SIP subscales dem-
onstrated greater disability in patients than controls [32].
The SIP and SIPV were highly correlated but, in this study,
over half the participants had diabetic retinopathy and
disability due to other diabetes-related complications
may well have influenced the result.
2.1.4 Vision-specific functional status (VF)
These measures investigate vision-related tasks such as
reading, writing, watching TV, recognising faces or driv-
ing. They are usually correlated with standard measures of
vision such as VA. However, because they do not differen-
tiate between what is relevant and what is irrelevant to
individual respondents, or what is important to QoL and
what is not, they are not true QoL measures, although
they are frequently referred to as such [10,12]. The impact
on QoL of loss of or deteriorating near vision would be
greater for someone who spent a lot of time reading and
doing embroidery than for someone who preferred listen-
ing to music and swimming. VF measurement has also
been shown to be influenced by general health [17]. For
example, the ability to prepare a meal may be affected by
arthritis as well as by vision and, if the questionnaire does
not specifically ask the respondent to consider only the
effects of their vision on a task, co-morbidity may con-
found the scores and make results difficult to interpret.
The Activities of Daily Vision Scale (ADVS) [33] was
found to discriminate between mild and severe MD (over-
all score, near vision, daytime driving and glare) but not
between mild and moderate MD [29]. The VF-14 [34],
originally designed for use with cataract patients corre-
lated more highly with patients' global assessments of
their vision than did VA in a Canadian study of 159 MD
patients [18] but MD severity did not predict VF-14 scores.
Since the VF-14 scores and patients' global assessments of
their vision are both effectively self-reports of vision func-
tion, it is not surprising that they correlated with each
other better than with a more objective measure of VA or
a measure of MD severity based on clinical features of the
eye. A Finnish study [35] reported similar properties for
the VF-14. A visual function measure designed for use
with MD and cataract patients is the Daily Living Tasks
Dependent on Vision (DLTV) questionnaire [36]. It was
found to correlate more strongly with distance VA in the
better eye than in the worse eye.
The 3 measures discussed above (ADVS, VF-14, and
DLTV) investigate only visual function and do not include
items relating to social or psychological functioning. The
Low Vision Quality of Life questionnaire (LVQOL) [37]
was designed for the evaluation of low vision rehabilita-
tion and does include a 3-item subscale relating to adjust-
ment. In a sample of 278 patients and 70 matched
controls, the measure differentiated between people with
normal vision and people with low vision. LVQOL scores
improved by an average of 17% following rehabilitation,
compared with people with normal vision, with reading
and fine work subscales most improved, but psychologi-
cal adjustment and other subscales also showed improve-
ment [37]. The NEI-VFQ [38], which has been well
validated in the MD population also investigates psycho-
logical aspects of visual impairment. As well as items per-
taining strictly to function, the NEI-VFQ investigates
social functioning, mental health and dependency. It dif-
ferentiates between different eye conditions and overall
score and relevant subscale scores are correlated with VA
[38]. It has been shown to be responsive to change in VA
over time [39], but this was in a large study over a long
period of time and the minimum change in VA investi-
gated was 3 lines of vision. A 3-line vision loss has been
used as the primary outcome measure in clinical trials for
treatments for MD (e.g. [40]). Two lines has also been rec-
ommended as a clinically significant change [41]. A meas-
ure may not be responsive in smaller samples over a
shorter period of time, when less change might be
expected to take place, if it cannot detect a change of only
two lines. It remains to be seen if the NEI-VFQ is suffi-
ciently responsive to detect two-line vision loss.
2.1.5 Vision-specific individualised quality of life measures
These investigate the impact of vision impairment on
QoL, examining both impact and importance of each
domain on QoL and allowing for variability in the rele-
vance of specific domains to individual respondents
[42,43]. Impact and importance scores are multiplied to
give weighted impact scores. The MacDQoL [42,44] meas-
ure of the impact of MD on QoL has two overview items
(present QoL and MD-specific QoL) and 23 domain-spe-
cific items. It has been shown to differentiate between
mild and moderate and mild and severe MD (measured
by UK registration status: blind, partially-sighted or not
registered) but, in common with visual function meas-
ures, not between moderate and severe. The overviewPage 4 of 20
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(generic) item less so than the MD-specific item, as would
be expected. There are promising indications of the
MacDQoL's responsiveness to change in a small sample
(Mitchell, Wolffsohn, Woodcock et al, manuscript in
preparation), and this warrants investigation in a larger
study. Measuring both the impact and the importance of
a domain of life to QoL leads to considerable variability
in scores and so correlations between the MacDQoL and
measures of vision such as VA or contrast sensitivity may
not be as large as those between VA and visual function
e.g. MacDQoL average weighted impact score correlates
0.45 with better eye distance VA [42], NEI-VFQ distance
vision score correlates 0.65 with better eye distance VA
[38] This latter correlation is perhaps not surprising since,
for the NEI-VFQ score and the distance VA score the
patient is being asked how well he or she can see in both
cases. The MacDQoL measure captures the nature of the
impact of MD on a person's life in a way that cannot be
achieved with a vision function measure. Any loss of sen-
sitivity to change in VA is outweighed by the increased rel-
evance of the QoL measure to the whole experience of MD
including experience of any treatment and rehabilitation.
2.2 Validation of questionnaires
Measures of health status, functional status, visual func-
tion and well-being are not, in themselves, QoL measures.
However, they are all concerned with aspects of life that
may be important to QoL.
The value of questionnaire data collected depends on the
psychometric properties of the measure. Psychometric
properties that are regarded as important in a measure
include [10]:
• Content validity: The extent to which the topic of inter-
est is comprehensively and relevantly investigated by the
measure. Patient involvement in the design of a patient
reported outcome measure is vital in ensuring content
validity.
• Face validity: The extent to which the questionnaire
appears to measure what it is intended to measure.
Researchers selecting questionnaires should consider the
questions carefully. They would then see that the EQ5D
(also called EuroQol) in fact asks about health and not
about QoL [11].
• Internal consistency reliability: The extent to which the
items contribute to measuring the same construct (a relia-
bility coefficient is calculated).
• Test-retest reliability: The extent to which scores remain
stable over time when no change has occurred (i.e. when
there has been no change in vision, no treatment for MD
or rehabilitation).
• Construct validity: Hypotheses concerning the relation-
ship of questionnaire scores to other measures (such as VA
or contrast sensitivity) are tested. Ability to discriminate
between levels of disease severity (e.g. between people
who are registered blind, partially sighted or not regis-
tered) is important, particularly for a visual function
measure, which would be expected to correlate strongly
with disease severity.
• Responsiveness: Sensitivity to real change over time (e.g.
deterioration in VA or contrast sensitivity).
• Interpretability: The extent to which change scores can
be interpreted and explained.
In addition to these psychometric properties, the burden
placed upon respondents should be considered (length of
questionnaire, complexity of language, relevance of the
questions) and that on administrators [45]. Where ques-
tionnaires are designed in one language and translated
into other languages, linguistic validation is required,
including cultural adaptation where needed [46]. Forward
and backward translations are necessary (preferably
reviewed by the questionnaire author) to ensure that the
translations have not introduced semantic discrepancies.
Clinician review can be helpful and cognitive debriefing
interviews with people who have MD are needed to
ensure that the translated items and instructions are
understood as intended. Psychometric evaluation of each
language version is necessary, at least on first use, before
analysing data from multiple languages as one dataset.
The method of administration is a further consideration
that is particularly important in visually impaired popula-
tions. Self-completion (pen and paper) has been found to
elicit poorer scores than interview administration in some
questionnaires [47-49] but not in others [33]. Where
scores differ, using two implementation methods in one
study may result in people with worse vision, and having
interview administration, under-reporting impairment
compared with people self-completing the measure. This
would confound the results. Generally it is better to use
only one administration method in any one study.
2.3 QALYs and other manipulations of PROs
A limitation of condition-specific or vision-specific meas-
ures of health status, functional status and QoL, even
when they are interpreted appropriately, is that the scores
are not comparable across diverse medical specialties
[50]. One use for outcome measures is to assess the rela-
tive cost-effectiveness of different treatments and to
inform decisions concerning allocation of limited funds.Page 5 of 20
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ditions and allow direct comparison, would be an asset
for health economists. One technique that is adopted
increasingly to achieve such comparisons is utility assess-
ment. Utility values (also called preference measures) are
quantitative expressions of preference for given health
states. A scale is used where utility values range from 0 to
1; 0 represents death and 1 represents perfect health. Tech-
niques used for eliciting this value include time trade-off
(TTO) and standard gamble (SG) (see below). The utility
value obtained can be used in conjunction with an esti-
mate of life expectancy to calculate Quality Adjusted Life
Years (QALYs). QALYs are estimates of life expectancy in
full health. One year of life in a health state rated as per-
fect health (utility value of 1) = 1 QALY. Two years of life
in a health state with a utility value of 0.5 = 1 QALY. Using
a figure for the cost of treatment, a cost per QALY can be
calculated. Such costs can be calculated for any clinical
intervention, and have been used by medical decision
makers such as the National Institute for Health and Clin-
ical Excellence (NICE) in the UK to make choices between
treatments. Health economists argue that non-preference
PROs correlate poorly with preference measures and so
are not suitable for use in economic evaluation [51]. It
could be argued that preference measures, although con-
venient for calculating QALYs, do not correlate well with
non-preference based measures as they do not measure
quality of life [52]. Evidence that this is the case will be
reviewed below. First, methods of obtaining utility values
will be considered.
2.3.1 Obtaining utility or preference measures
Time trade off
Participants are asked first how many more years they
expect to live. They are then asked how many years of their
remaining life they would be willing to give up if they
could have a (hypothetical) treatment for their medical
condition that would guarantee them perfect health for
their remaining years. For example, if someone expected
to have 20 years of life remaining, and were willing to give
up 10 years in return for perfect health, then that person
would be said to have given their medical condition a util-
ity of 0.5.
Standard gamble
Participants consider two alternatives a) a treatment with
two possible outcomes: either perfect health for the
remainder of their life or immediate death b) the certainty
of a chronic health state for life. Participants are asked to
say what percentage risk of death they would be prepared
to accept to avoid the certainty of having the chronic
health state for the rest of their lives. Again the data are
used to obtain a utility value of between 0 and 1.
A number of studies by a US research group have reported
utility values for MD using TTO or SG techniques [53-58]
and there has been reasonable concordance in the find-
ings. A British study reported that utility values were more
strongly associated with contrast sensitivity than VA [26].
Nevertheless the method has attracted criticism. For exam-
ple, there is some debate about whose values are the most
appropriate: patients', doctors' or those of the taxpaying
general public [59]. The general public may be unaware of
the impact of some medical conditions unless they them-
selves are affected by the condition. There can be marked
differences in the values of patients, doctors and the pub-
lic [60] and the decision to use one group rather than
another will therefore be likely to affect the results
obtained. It has also been reported that demographic data
may be more predictive in determining health state utili-
ties than the health states themselves [61]. Some studies
have reported less than impressive response rates [62,63].
Others have avoided reporting response rates (e.g.
[53,54]). TTO questions are often posed to patients dur-
ing an eye clinic appointment while they wait to see the
ophthalmologist following dilation of the pupils. Patients
may feel vulnerable and disempowered at this time and
reluctant to express unwillingness to take part. When par-
ticipants in a UK study were asked TTO questions during
a telephone interview while they were in their own home,
at a time convenient to them, response rates were a cause
for concern [52]. A large proportion of people who did
respond (38%) said they would trade no time for perfect
vision. Unsolicited comments from participants indicated
that they thought the questions ridiculous, too hypothet-
ical or objectionable for religious or other reasons. People
said they would not trade time because they were carers or
because they wanted to see their grandchildren grow up.
Nevertheless, it is likely that improvement in their MD
would improve their QoL. There was no relationship
between utility values and vision status (registration as
blind, partially sighted or not registered) whereas, in the
same study, vision status was significantly associated with
MacDQoL scores. Another UK study [64] demonstrated
that 50% of participants with varying severity of MD were
not prepared to trade any time for perfect vision and, after
removing scores where no time was traded, there was no
relationship between TTO utility values and VA. It is likely
that the questions posed in the TTO method would be
particularly difficult for elderly people to answer given
their shorter life expectancies. The comparability of TTO
responses to questions about 'perfect health' and those
referring to 'perfect vision' must also be questioned. A per-
son with poor vision and poor general health might view
things differently from a person who has poor vision but
otherwise good health.
Opinions differ as to whether utility values should be
obtained from patients, health professionals or the tax-Page 6 of 20
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mate the impact of medical conditions on QoL compared
with patients [9]. However it has been shown that MD is
an exception to this rule: both the public and health pro-
fessionals report higher utility values for MD than do
patients [60]. This perhaps reflects an underestimation of
the impact of the loss of central vision and an overestima-
tion of the value of peripheral vision. Whatever the rea-
son, a comparison of utility values across diseases when
the utilities have been obtained from the public would
mitigate against resources being allocated for treatment
and rehabilitation of people who have MD.
3. Impact of MD
3.1 Psychological well-being
A number of studies have looked at the impact of MD on
psychological well-being. In an American cross-sectional
study investigating 86 MD patients with a VA of 20/200 or
worse in at least one eye [30] participants reported greater
emotional distress (Profile of Mood States [POMS] [65])
than similar aged people without visual impairment.
Scores were comparable with those of people with serious
illnesses such as melanoma and HIV. Poorer functional
status (QWB [66]) was associated with greater emotional
distress. Longer duration of MD was associated with lower
levels of emotional distress, probably due to adaptation to
the condition. Lack of adaptation, particularly the per-
sonal experience of vision loss as opposed to its effect on
relationships, was associated with depression in an Amer-
ican study of 144 MD patients [67].
A further US cross-sectional study of 151 patients with
advanced MD (VA of 20/60 or worse in the better eye)
[68] reported that the rate of depressive disorder (32.5%)
(DSM IV [69]) was twice that found generally among eld-
erly people living in the community. The strongest associ-
ations found were between depression (DSM IV [69]) and
both vision-specific (NEI-VFQ [38], SIPv [32]) and gen-
eral disability (SIP [31]). There was only a weak associa-
tion between VA and depression. In cross-sectional
studies there is a potential reciprocal relationship between
visual disability and depression (disability leads to
depression and depression influences disability) [70], but
in a longitudinal study causal effects in such relationships
can be established.
A prospective, longitudinal US study recruited MD
patients with recent (6 weeks previously) loss of vision in
their second eye [70]. At baseline 17 (33%) of 51 partici-
pants met the criteria for clinical depression (a higher rate
than the 16% found in the community) of whom only
one was receiving treatment for depression, suggesting
low levels of pre-existing depression. This group had
poorer VA, and greater visual disability (Functional Vision
Screening Questionnaire [FVSQ] [71]) and general disa-
bility (Community Disability Scale [CDS] [72]) than the
non-depressed group. Six months later 40 people were
followed up (people who dropped out tended to be more
depressed at baseline than the follow-up participants). In
people depressed at baseline and still depressed at follow-
up (N = 7), those whose depression worsened had a cor-
responding decline in general and visual function inde-
pendently of any change in VA.
Visual impairment in the elderly has been shown to be a
predictor of suicide [73].
Decline in visual function inevitably leads to difficulties
in performing daily activities and also in pursuing leisure
activities. In a US study of 51 MD patients [74], 36
reported that they had lost valued activities as a result of
impaired vision, reading and driving being the most com-
mon. In this sample, the relationship between VA and
depression was mediated by loss of valued activities. In a
postal survey of 2000 members of the UK Macular Disease
Society using the Macular Disease Society Questionnaire
(MDSQ) (Mitchell J, PhD thesis, Royal Holloway, Univer-
sity of London 2003) [75], 832 of 1420 respondents
reported a reduction in the number of hobbies pursued
due to vision loss since the onset of MD. In the entire sam-
ple the mean number of hobbies reported before MD was
3.54 compared with 2.20 at the time of the survey. Read-
ing, enjoyed by 59% before diagnosis, but by only 20% at
the time of the survey, was the most curtailed hobby, and
crafts and driving were also severely affected. Poorer Well-
being (W-BQ12), Present QoL and MD-specific QoL
(MacDQoL overview items) were all associated with loss
of leisure activities after controlling for severity of MD
(registration status). Data from the MacDQoL [42,44]
indicate that the domain of leisure activities is one of the
most highly negatively impacted by MD.
Impaired efficiency in carrying out activities of daily life
can compromise cherished independence [76]. In a study
of 156 people with MD, independence was the most
highly negatively impacted domain of the MacDQoL [42].
An Australian qualitative study [77] reported that losing
the ability to drive is a major factor in loss of independ-
ence and, as well as having to rely on others for mobility,
can lead to social isolation, in itself a factor in the progress
of depression. This study also indicated that people resist
asking for help for fear of becoming a burden and go to
great lengths to remain independent.
Loss of independence in MD may be such that it is neces-
sary to go into residential care. Visually impaired people
are over-represented in care homes [78-80] where it is
associated with elevated levels of depression [81]. Chali-
foux [82] asserted that people with MD may be pressured
by their families into entering residential care for theirPage 7 of 20
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encouraged to remain in the community for as long as it
is practically possible.
Visual impairment due to MD may lead to unplanned for
expense. In this elderly population, many of whom have
very limited resources, financial outlay related to vision
impairment may lead to hardship. Nevertheless, a French
study found that people with MD pay for help in the
home [83] and that expenses increased with worse VA.
British research indicates that people spend money on
optical and other devices [84]. Tasks such as home main-
tenance and dressmaking may have to be paid for where,
prior to MD, people were able to carry out the work them-
selves. Some forms of treatment, such as photodynamic
therapy (PDT), are expensive and may have to be paid for
personally if National Health Service or insurance
schemes will not allow the treatment. Treatments for con-
ditions resulting from MD, including depression and frac-
tures due to falls, may also be expensive [85]. 'Finances'
was one of the least impacted domains of the MacDQoL
[42,44] but even so there was a good deal of variability in
the scores of both impact and importance on the finances
domain, showing that, for some people, finances are
important for QoL and are negatively impacted by MD.
There is a positive association between increasing age and
poorer sleep quality [86]. Sleep disturbance is itself asso-
ciated with depression and other somatic symptoms and
causes a deterioration in quality of life [86]. In a study of
6,143 elderly Scandinavian people, Asplund found that
poor sleep, difficulty falling asleep and frequent awaken-
ings were all more common among visually impaired
men and women than in those without visual impairment
[86]. It is possible, therefore, that the sleep deprivation
experienced by people with MD may contribute to ele-
vated levels of depression.
3.2 Life satisfaction
Only one study was found that reported the relationship
between life satisfaction and MD. A small Australian
cross-sectional study reported that people with MD (N =
30) reported poorer life satisfaction (Life Satisfaction
Index – well-being) [87] social support and greater stress
due to daily hassles than a control group without MD of
similar age [88].
4. Perceived quality of health care, satisfaction 
with the diagnostic consultation and their 
relationship to patient well-being
In the MDSQ study [75], 1420 respondents answered
questions about their experiences at diagnosis. More than
half, 735 (54%) thought their consultant was not inter-
ested in them as a person and 41% were dissatisfied with
their diagnostic consultation. The attitude of the consult-
ant and lack of information were the most frequently cited
reasons for dissatisfaction (each cited by 43%). W-BQ12
scores were significantly poorer for those who were dissat-
isfied and for those who thought their consultants were
not interested in them. In this cross-sectional study cau-
sality cannot be established but other data from the ques-
tionnaire added weight to the suggestion of a causal
relationship. For example, the difference in well-being
between the satisfied and dissatisfied groups was greater
in more recently diagnosed people (< 2 years) than in
those who had had MD for longer (Mitchell, 2003).
During the recent development of a measure of macular
service satisfaction (MacSSQ) [89], items relating to
aspects of the diagnostic consultation including provision
of information, advice and support and the opportunity
to ask questions were those that were most consistently
rated as unsatisfactory by people taking part in focus
groups and pilot work. Wong et al [77] said that the most
striking feature of in-depth interviews in a qualitative Aus-
tralian study of people with MD relating to the partici-
pants' psychosocial well-being was the importance of
'understanding' the condition. A focus group study in
Sweden [90] demonstrated that people with MD wanted
more information about many aspects of their condition
and its consequences, including how they might prepare
for a future with severe visual impairment.
The majority of MDSQ respondents (1247 (90%)) had
been told that 'nothing can be done to help with your
MD'. Of those 757 (61%) said they felt depressed or anx-
ious on hearing this news and 54 (4.3%) said it led them
to feel suicidal. Similar experiences at diagnosis were
reported by MD patients in Australia [77].
The Royal College of Ophthalmologists' guidelines for the
management of MD [91] stress the importance of early
provision of information and support. Future research is
needed to assess the extent to which the recommenda-
tions have been effective as far as the patients are con-
cerned.
5 Extent of impairment
5.1 Bilateral and unilateral involvement
Williams et al [30] compared people with one or both
eyes affected by MD in the US and found that those who
were legally blind in only one eye reported greater emo-
tional distress than those with bilateral blindness. Anec-
dotal evidence of greater distress among people with some
vision in one eye compared with those with no vision was
reported in much earlier work [92]. In both articles, fear
of losing vision in the second eye was suggested as the
cause of the greater distress. In contrast, in the MDSQ sur-
vey (Mitchell, 2003) respondents with only one eye
affected reported better psychological well-being (W-Page 8 of 20
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of men and women with varying severity of MD [77]
found that people with only one eye affected reported that
MD did not affect their day to day living but they worried
about the future and the possibility of second eye involve-
ment.
5.2 Dual sensory impairment
Many people experience deterioration in their hearing as
they get older. When this is accompanied by visual
impairment there can be considerable impact on QoL.
Three population studies investigating dual sensory
impairment in the elderly [93-95] reported that both
vision and hearing impairment impacted negatively on
FS, with visual impairment having the greater effect. These
studies had only small numbers of participants in some of
the impairment categories and relatively blunt measures
of impairment were used but nevertheless they were able
to report that dual sensory impairment had a greater
impact than either visual or hearing impairment alone
[93,94]. A large, longitudinal population study of older
women (N = 6112) [96] reported that vision impairment
alone, but not hearing impairment alone was associated
with both functional and cognitive decline and women
with dual sensory impairment were at greatest risk of func-
tional and cognitive decline. Another population study of
elderly people [97] relied on self-report of both vision and
hearing impairment and a number of symptoms of
depression. In spite of these rather crude measures, it was
found that all three sensory loss groups (vision, hearing
and dual) were more likely to report depressive symptoms
than those without impairment, with greatest risk in the
dual impairment group.
5.3 Co-morbidity
In studies of elderly populations it is likely that many peo-
ple will have other medical conditions in addition to MD.
Williams et al [30] reported that 66 of 78 participants with
MD had other medical conditions. When compared with
those in the sample who had MD as their only medical
problem, there was no difference between the two groups
in emotional distress, difficulties with IADLs, self-
reported general health and functional status (QWB).
Only 18% rated another of their medical conditions as
worse than MD – a point that health economists would
do well to take note of. A large, multinational study (Can-
ada, France, Germany, Spain, UK) [98] found that neovas-
cular MD patients had significantly more co-morbid
conditions than a control group (2.5 vs 2.2) and the MD
patients were more likely to have had cancer (9% vs 4%)
and stroke (4% vs 1%). Falls were twice as common in the
MD group (17% vs 8%) [85]. Conditions associated with
age such as arthritis and osteoporosis can, for people with
MD, further compromise their dexterity and confidence in
carrying out daily activities, their ability to get out and
about or to enjoy leisure activities and the effect may well
be to reduce their QoL.
MD can also be the cause of co-morbidity. Hip fracture is
common in the frail elderly population and visually
impaired people are over-represented in this group of
patients [99-101]. Dutton commented that a familiar
experience for ophthalmologists is to send away a newly
diagnosed woman with MD without follow-up or referral
to other services because her VA does not warrant it only
to have her return to the clinic some months later with a
much reduced VA and a consequent fractured hip which
has resulted in her being taken into residential care [102].
A commonly co-occurring eye condition for people with
MD is cataract. The presence of MD has been implicated
in poor visual outcome following cataract surgery and
some evidence suggests that the treatment may even
worsen the progress of MD [103]. Several studies, how-
ever, have indicated that cataract surgery leads to
improved vision function for MD patients [103-105].
There is evidence to indicate that visual impairment car-
ries with it an increased risk of mortality. McCarty et al
[106] reported that VA worse than 6/12 more than dou-
bled the risk of mortality over a 5-year period. The
increased risk may be due to incidents such as falls or car
accidents [106]. People with visual impairment may also
be more prone to accidents in the home such as fires or
mishaps with electrical appliances.
5.4. Visual hallucinations: Charles Bonnet Syndrome
Visual hallucinations, known as Charles Bonnet Syn-
drome, are common in people with visual impairment. In
a survey of eye clinic patients with MD (N = 100), 13%
reported experiencing formed visual hallucinations [107].
Only five of these had reported the hallucinations to their
doctors. Of 86 consecutive patients at a retinal clinic (24%
with MD), 13 (15%) said they experienced visual halluci-
nations [108]. Two of those participants had reported the
hallucinations to a doctor. Two hundred and eighty two
(20%) of the 1420 respondents to the MDSQ said they
had experienced hallucinations at some time since diag-
nosis with MD [75]. Over 40% (122) of these had spoken
to a health professional about the hallucinations of whom
59 (21% of those experiencing hallucinations) were given
an explanation. Some explanations were inaccurate or
unhelpful e.g. psychological (N = 1), brain confusion (N
= 1), stress (N = 2), nothing to do with MD (N = 1). In a
study of 100 patients treated with PDT for predominantly
classic CNV, five (5%) described experiencing structured
hallucinations following treatment [109].
These studies indicate that people may be reluctant to
report hallucinations for fear of being diagnosed withPage 9 of 20
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concern alone may impact on QoL, severity of MD and
hallucinations notwithstanding. Mitchell reported that
hallucinations were associated with poorer psychological
well-being (W-BQ12 [15]) after controlling for severity of
MD (Mitchell, 2003). Scott reported that, even among
people with relatively good VA, those experiencing hallu-
cinations demonstrated higher levels of emotional dis-
tress (General Health Questionnaire [GHQ] [110]) and
decreased function (SIP [31]) compared with those with-
out hallucinations [108]. Health professionals need to be
aware of the likelihood of hallucinations in MD and ask
patients if they have experienced them. Reassurance about
the benign nature of the phenomenon and its often lim-
ited duration would prevent much distress [111,112].
Cohen et al [109] suggested that all patients who undergo
PDT should be told beforehand that hallucinations are a
possible side effect of treatment. Such pre-emptive educa-
tion may be the best approach for all people diagnosed
with MD [89].
6. Rehabilitation
People with MD may not understand the nature of the
condition and consider it to be part of the ageing process
[90]. If rehabilitation is to be successful, it is important
that they appreciate that it is a medical condition, with
disabling effects, many of which can be prevented or
reduced [90] and that help is available.
The emotional impact of vision impairment is frequently
discussed in terms of the 'loss model' [113]. According to
this model vision loss is akin to bereavement and the
patient will usually go through the stages of mourning,
including shock, denial, anger and depression (which
may take months) before rehabilitation can be effective.
Dodds [114], however, asserted that depending on exter-
nal support during depression may lead to helplessness
that would later mitigate against effective rehabilitation
and that the patient's own perceived incompetence result-
ing from a lack of early rehabilitation would lead to
demoralization and depression. He recommended early
intervention.
6.1 Low vision aids provision and training
Low vision services, including assessment of vision and of
patients' needs, LVA provision and training have been
shown to lead to improved visual function (VF-14, four
subscales of NEI-VFQ) [23] and to lead to better visual
function compared with a control group (LVQOL) [37].
Better psychological status (less depression and more self-
confidence (Geriatric Depression Scale [GDS] [115]) at
the time of rehabilitation has been shown to be associated
with better outcome (reading speed and accuracy, critical
print size) [116]. An interdisciplinary service including
contributions from optometrists, ophthalmic nurses,
social workers and rehabilitation officers resulted in
improvements to visual function (VQOL [117]) and fewer
problems in daily living (Manchester Low Vision Ques-
tionnaire [MLVQ] [118]) [119]. One study by Reeves et al
compared standard low vision care with enhanced regi-
mens but found that no benefit accrued from the addi-
tional help [120]. The enhanced programme involved
further training in the use of LVAs and provision of alter-
native LVAs if necessary. It also incorporated advice on
lighting and other features of the home environment dur-
ing the course of a single home visit by a rehabilitation
officer. The 'enhancement' may simply have been too lit-
tle. For example, other work [121] indicated that standard
low vision care followed by additional teaching sessions
enabling extra tuition, correction of poor skills, additional
practice with more difficult tasks and answering patients'
questions over a 4 week period resulted in improvements
in vision function (NEI-VFQ) and reading speed (Pepper
VRST) compared with a group who had only standard
care. Although there was no measurable improvement in
VA, the experimental group reported improvements in
self-rated eyesight. Whereas in the Reeves et al study [120]
participants were given advice on lighting in the home,
low vision centres in Sweden go further by upgrading
lighting in the homes of patients (in kitchen, hall and
bathroom) where necessary. A study to evaluate the bene-
fits of improved lighting provision [122] indicated
improvements in some ADL performance (mainly in
kitchen and bathroom) with better lighting, although
there was deterioration in other ADLs, possibly due to
deterioration in vision during the study. As part of the
study, half the participants were provided with optimum
task and mood lighting in the living room (according to
individual needs). The control group reported improve-
ments in general health, self-confidence and loneliness
(not from a published scale), but not to well-being (Psy-
chological and General Well-being Index [123]) at 6
months after light adaptation. The intervention group
showed significant improvements in the same items but
also reported improved physical condition, appetite,
social contacts, self-confidence, temper, depressed mood,
vitality and well-being (not psychometrically evaluated
measures). As the living room is a place associated with
leisure, it may be that enhanced ability to enjoy valued lei-
sure activities influenced perceptions of these constructs.
This possibility chimes with evidence cited in section 3.1
that loss of valued activities is associated with increased
depression. Other work suggested that increases in illumi-
nance of task lighting leads to improvements in contrast
sensitivity and near VA [124] and the authors suggested
that provision of additional task illuminance should be
part of low vision rehabilitation.
Training in eccentric viewing has been shown to improve
reading speeds [125]. No PROs were used in this study,Page 10 of 20
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has indicated the impact of losing reading fluency due to
MD and it is likely that there would be a positive impact
on QoL for people trained in eccentric viewing or assisted
by low vision aids to regain reading fluency.
6.2 Psychosocial interventions
Psychosocial interventions to assist adjustment to MD are
not generally available in health-care settings [126] but a
number of studies offer evidence for the benefits of such
programmes. In Sweden a course of eight weekly 2-hour
meetings for groups of 4–6 people with bilateral MD led
by occupational therapists was evaluated initially by qual-
itative focus group methodology [90,127]. Participants'
endorsement of their increased knowledge of MD, the
social support offered by the meetings and improved self-
efficacy in performing activities of daily living was sup-
ported by long-term evaluation of the course (28 months
later) using quantitative methods [128]. Activities of daily
living were investigated in the areas of meal preparation,
self-care, communication, cleaning, mobility, shopping
and financial management. Compared with people who
had experienced standard care, those taking part in the
courses reported higher levels of perceived security in per-
forming 15 of 28 daily activities investigated including
items relating to meal preparation, cleaning, mobility,
communication and financial management. Self-care and
shopping-related items were unaffected. Within the exper-
imental group, participants reported improvement in 14
of 28 items at the 28 month evaluation, including items
relating to meals, communication, cleaning, mobility and
financial management. The control group reported lower
levels of security in 12 of the 28 activities investigated,
including items relating to meals, communication, clean-
ing, mobility, shopping and financial management. These
findings illustrate the importance of education and sup-
port in preventing a decline in perceived security in per-
forming ADLs as well as enabling greater perceived
security.
A self-management intervention consisting of 6 weekly 2-
hour group sessions was developed in the USA [129]. It
included presentations, lectures, problem-solving and
skills training with guided practice using cognitive-behav-
ioural principles. Compared with a waiting list control
group, participants reported improvements in emotional
distress (POMS) and self-efficacy (scale developed for the
study) and their use of LVAs almost doubled. Self-
reported functional capacity and symptoms (QWB) did
not improve. In a larger study using this programme, par-
ticipants with higher baseline levels of depression
reported greater improvements (POMS) compared with
less depressed people in the experimental group and with
depressed people in the control group. The experimental
group showed improvements in vision function (NEI-
VFQ) compared with controls (especially those more
depressed at baseline). Improved self-efficacy was associ-
ated with decreased depression. The effects of the inter-
vention were sustained at 6-month follow-up [130] when
depression was lower overall in the experimental group
than in the control group.
A cognitive-behavioural-based programme developed in
Germany incorporated modules relating to relaxation,
awareness of the associations between thought, emotion
and behaviour, maximising personal and external
resources, exchange of personal experience and provision
of information [126]. In this small pilot study, the course
of 5 weekly 2-hour sessions resulted in the experimental
group (N = 14) reporting improvements in negative affect
and depression (Positive and Negative Affect Schedule
[131], GDS [115]), performance of ADLs (Multilevel
Assessment Instrument [132], modified), personal auton-
omy (developed for study) and active problem orienta-
tion (Freiburg Inventory on Coping with Illness [133])
compared with the control group (N = 8).
In Leicester, UK, in a programme of peer support, 6
weekly 1 1/2-hour discussion groups were led by 3–4 peo-
ple with at least 5 years' experience of living with MD
[134]. Participants received leaflets which acted as guide-
lines for each topic for discussion in the group. Participant
course evaluation indicated that the leaflets had given
them useful information and that the aims of the course
(to provide information about MD, to provide friendship
and support and to help adjustment to MD) had been
met. This was a small pilot study with 2 groups of 6 par-
ticipants each. The sessions were well attended. Data indi-
cated that people who reported poorest well-being (W-
BQ12 [15]) at the start of the course showed significantly
more improvement in well-being following the interven-
tion. Thus greatest benefit was experienced by those most
in need. Ten of the 11 participants completing question-
naires at follow-up said they would be willing to help run
similar groups in the future for others newly diagnosed
with MD, providing further evidence that the programme
of peer support was beneficial for them and, with their
assistance as future course leaders, could be rolled out to
others.
6.3 Levels of rehabilitation and support
Evidence shows that rehabilitation offers benefits to func-
tional status and a number of psychological outcomes.
Nevertheless, the services offered are patchy. A survey of
588 blind and partially sighted older people (with eye
conditions including MD) in the UK [135] reported poor
levels of support and care, with only 53% of participants
having had a home assessment, around half receiving
help with household tasks and shopping and as few as 7%
receiving meals on wheels. Many lived isolated lives, withPage 11 of 20
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person less than once a month. It was estimated that 82%
of those who lived alone were in poverty. Although all the
people in the survey were eligible for registration as par-
tially sighted or blind, only 58% knew of a local society
for visually impaired people. There was a similar picture
of inadequate provision of low vision aids and equipment
to help with cooking and housework. In a survey in West
Glamorgan of people registered blind or partially sighted
[84], of 66 participants (39 with MD) only 80% had been
visited by a social worker. Few possessed safety or mobil-
ity aids although all those who had them found them
helpful. Kitchen aids, tactiles (e.g. raised buttons stuck on
to oven controls to indicate temperature settings), and
talking timepieces were also owned by only a minority.
Distribution of aids was irregular with some owning sev-
eral and others none at all. Many people were not aware
of the financial benefits that might be available to them.
Clearly there are many improvements that could be made
to rehabilitation services for people with MD. Although
none of the rehabilitation studies reviewed here measured
the effect of interventions on QoL, many reported
improvements in outcomes that may contribute to QoL.
7. Medical treatment
In the Sub-Foveal Radiotherapy Study [19], the small clin-
ical benefits of treatment of sub-foveal choroidal neovas-
cularisation were not reflected in improvements to visual
functioning (DLTV) or health status (SF-36) in a longitu-
dinal analysis of a randomised clinical trial involving 199
participants (99 treatment, 100 control).
Submacular surgery trials initially used the SF-36 health
status measure as the only PRO in the pilot study [20].
Changes in VA over the two year period of the study were
not associated with changes in SF-36 scores. In the main
trial the SF-36 was used again together with the Hospital
Anxiety and Depression Scale (HADS) and NEI-VFQ. At
enrolment, VA was associated with NEI-VFQ scores but
not with HADS or SF-36 scores [28]. At follow-up [21] (2
years after enrolment) there were no significant changes
in any of the PRO scores although participants in the treat-
ment group were less likely to lose ≥ 6 lines of VA than the
control group.
In a study of 50 patients who underwent macular translo-
cation [24], pre-and post-operative visual function (NEI-
VFQ) and general health status (SF-12) were measured.
Overall vision function (NEI-VFQ) improved post-opera-
tively and specifically in the subscales measuring general
vision, difficulty with distance vision tasks, difficulty with
near vision tasks, dependency, mental health and social
function. Improvement in near and distance VA was asso-
ciated with greater improvement in function (NEI-VFQ).
Reading speed improved for 29 patients and this was asso-
ciated with improvements in NEI-VFQ scores. Not surpris-
ingly, there were no changes to SF-12 scores. Other work
has reported improvements in reading speed following
macular translocation [136,137].
Photodynamic therapy (PDT) for the treatment of sub-
foveal neovascular MD has undergone extensive trials, but
there has been little effort to measure its effect on QoL or
any other PROs that may influence QoL. In one prospec-
tive study of PDT [138], at 12 months follow-up, 34 of 48
treated patients had lost fewer than 3 lines of VA and, on
average, the sample lost fewer than two lines. VF-14 items
showed either no change or a decrease in function, con-
sistent with the VA changes. Participants reported being
less anxious because of MD and that they stayed indoors
less, but this may have been due to adjusting to living with
MD. There was no control group in this study.
An unusual attempt to assess the impact of PDT on so
called 'QoL', was based on a computer-generated model
[56]. Hypothetical patients (characterised using data from
the TAP study [139]) were the 'participants'. Utility values,
acquired using TTO, were obtained by the researchers
from Canadian patients with MD (N = 40) and utility val-
ues were calculated for a range of VA values. Utilities asso-
ciated with loss or non-loss of three lines of vision over
two years were calculated and the authors incorporated
'disutilities' judged to be associated with complications of
PDT (determined only by ophthalmologists). The model
was used to estimate QALYs gained as a result of PDT.
Sharma et al calculated that a gain in QALYs of 11.3%
could be expected from PDT. Sharma et al misleadingly
used the terms 'QALYs' and 'utilities' interchangeably with
'QoL' suggesting that they were unaware of the poor rela-
tionship between TTO measures and measures of the
impact of MD on QoL [52]. TTO and SG measures
favoured by health economists are so far removed from
patients' experience of the impact of MD on their QoL that
it is a major source of concern that such studies may be
used by NICE to determine which, if any, patients with
MD will receive treatment on the National Health Service.
NICE has taken the view that taxpayers, rather than
patients, should be involved in decisions concerning the
allocation of public funds for medical treatments and, in
some determinations of utility values, panels made up of
members of the public are used to elicit data [51]. Panel
members are given descriptions of the medical conditions
or health states and asked to evaluate their utility. Other
exponents of value-based medicine do at least recom-
mend that the utility values obtained from people who
have the condition concerned should be used in prefer-
ence to utility values estimated by surrogates [140].Page 12 of 20
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the growth of new blood vessels characteristic of wet MD,
have been promising. In a study of ranibizumab (Lucen-
tis) in people with minimally classic or occult MD, treat-
ment groups showed significant improvements in NEI-
VFQ scores (near and distance activities and dependency)
over one year compared with controls [141]. A one-year
study of the effects of pegaptanib sodium (Macugen)
compared with sham treatment [142] showed improve-
ments in some NEI-VFQ subscale scores in the Macugen
treated groups compared with controls but other sub-
scales showed no change, possibly due to small subgroup
sizes. Both of these abstracts refer inappropriately to QoL
while actually reporting visual function. However, the
results certainly look promising for QoL (providing that
the experience of treatment with intraocular injections is
not too distressing) even though QoL has yet to be meas-
ured.
A small study (30 intervention,15 controls) evaluated the
effect of carotenoids and antioxidant supplementation in
people with intermediate or advanced MD [143]. After
one year, people with intermediate MD showed stabilized
VA, better VA than controls and improved NEI-VFQ 39
visual function scores, while these deteriorated in the con-
trol group. There was no benefit found in the advanced
MD group.
Several of these trials show promising results in terms of
visual function but, while some have claimed to measure
the impact of treatment on QoL, none has actually done
so.
8. Future research
A diagnosis of MD will inevitably impact not only on
patients but on those people closest to them. There may
be concerns about genetic transmission of the condition
to sons and daughters. A partner or other family member
is likely to experience anxiety about the diagnosis and
prognosis. Worry about the future and the patient's possi-
bly deteriorating vision will affect those closest to him or
her. Retired couples often enjoy shared interests and,
where these are lost to the patient, they may also be lost to
the partner. This may lead to resentment and frustration.
There is also the possibility that people will over-compen-
sate for the difficulties brought about by MD and make
the person with MD unnecessarily dependent, preventing
successful adjustment to the condition. People who
develop MD are sometimes carers themselves and an ina-
bility to continue effectively in this role can lead to diffi-
culties [144]. The cared-for person may then have to
depend on more formal care, with the expense and dis-
ruption that it involves. People with MD may themselves
have to be cared for. This sometimes entails moving in
with their family and it is unlikely to be without conse-
quences. There appears to have been no research carried
out into this aspect of living with MD and findings from
such studies may be helpful in showing how people with
MD can most effectively be supported.
Although there has been research into LVA provision and
training, only one study was found that reported investi-
gation of the usefulness of specific devices [145]. The
study reported that, in general, conventional optical aids
were preferable to head-mounted devices for older users.
However, participants did not select the devices they tried
but were randomised to two of four devices. It may have
been more informative if people had been able to choose
which devices they tried, so overcoming any antipathy
towards a particular device. More research is needed into
the benefits of aids such as closed circuit television, port-
able electronic magnifying devices and voice-activated
computer software.
In the UK, several hospital eye clinics make arrangements
for volunteers with MD to set up a hospital volunteer sup-
port service to provide immediate information and sup-
port for people newly diagnosed with MD. Anecdotal
evidence suggests that these services have been valuable
and much appreciated by those who have been able to
talk to volunteers and make contact with local MD groups
and LVA services. A carefully designed evaluation study of
the existing hospital volunteer services is needed, includ-
ing clinics with and without such services, and further
evaluation following introduction of new volunteer serv-
ices where there were none previously. The MacSSQ meas-
ure of satisfaction with the service provided has been
designed for such a study and may supply compelling evi-
dence to encourage hospital eye clinics to be more open
to such innovations, providing much needed initial help
and support to bewildered patients. Peer support groups
such as those pilot tested in Leicester [134], recruiting via
hospital volunteers, also warrant evaluation in larger scale
intervention programmes.
With new treatments being developed there is a need for
treatment satisfaction to be evaluated. While possible new
treatments for MD are welcome, patients may experience
difficulties with them in a number of ways including side
effects, apprehension, discomfort or distress caused by the
method of administration, frequency of treatment and
efficacy of treatment. Investigating patient satisfaction
with treatment can lead to improvements that make treat-
ments more acceptable to patients [146]. Foundations
have been laid to develop an MD treatment satisfaction
questionnaire, following the procedure used in the design
of the RetTSQ measure of satisfaction with treatment for
diabetic retinopathy [146].Page 13 of 20
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Quality of life has been conceptualised in a number of
ways in research into the impact of MD. Well-being,
health status, functional status and visual function have
all been referred to more or less inappropriately as QoL.
We have argued that the use of such measures can be mis-
leading, resulting in misinterpretation of findings. Never-
theless, PRO instruments other than QoL measures
provide valuable data and, together, a variety of types of
measure can give a fuller picture of the effect of MD on
people's lives. Some measures, such as health status ques-
tionnaires are clearly not helpful in evaluating the effects
of MD. The SF-36 is a comprehensively validated and
widely used measure and it may be that it is selected
purely on the grounds of its ubiquity. If it is not expected
to yield relevant results, however, it is an unnecessary bur-
den on participants and is likely to give an underestima-
tion of the benefits of an intervention designed to
improve vision. In any study or clinical trial, careful
thought must be given to the choice of measures to ensure
that the data collected are the data that are required to
answer the research question or investigate the effect of an
intervention. A treatment for MD may result in enhanced
visual function but, if the treatment is very unpleasant,
has to be repeated regularly and is anticipated with trepi-
dation by some patients and refused by others, then it
might do substantial damage to QoL in spite of having the
potential to improve visual function. The work reported
here indicates that, in many cases, there is widespread
confusion about the term 'quality of life' and, generally,
the choice of questionnaire indicates that it is defined
inadequately. Choice of PRO instrument notwithstand-
ing, measuring the impact of vision impairment is com-
plicated by the involvement of a second eye and the
interactions between the two eyes' visual status [12].
Utility measures are increasingly used to estimate so
called 'QoL' gains or losses. The QALY values obtained
using TTO and SG methods are not measuring QoL [12]
and such measures give no impression of the ways in
which MD impacts on people's lives. There are many rea-
sons why a person may not want to relinquish any years
of life in spite of serious visual impairment but this does
not imply that they are content with the present situation
or that their QoL would not be much better without their
vision problems. When such measures are obtained from
members of the public who have no awareness of living
with MD the results are so far removed from the patients'
experiences as to be completely irrelevant to QoL meas-
urement. These inadequate and inappropriate measures
and others like them have been the preferred instruments
for 'QoL' measurement and continue to be used uncriti-
cally in organisations such as the UK's NICE [26], domi-
nated by health economists who are committed to such
inferential methods of measurement, unaware of the
importance of psychological factors and unaccustomed to
listening to patients' accounts of their own experiences
and descriptions of the impact of MD on their lives.
What emerges from the work reviewed here is that MD has
a damaging effect on many aspects of people's lives. The
loss of central vision associated with MD impairs impor-
tant aspects of visual function including reading, driving,
recognising faces, watching TV and other near vision activ-
ities. Impaired visual function affects different people in
different ways. Not all aspects of impairment will be
important to all people with MD but evidence from stud-
ies using the MacDQoL shows that loss of visual function
will affect all people with MD in some way [42,44]. The
extent to which MD impacts QoL will be influenced by
individual lifestyles and personal characteristics as well as
by factors such as social support, co-morbidity and access
to related services including training in the use of low
vision aids.
A good deal of evidence indicates that poor psychological
well-being and depression are more prevalent in people
with MD than in the population at large. Depression has
been associated with loss of valued activities [74] and with
poor experiences at diagnosis, including being told that
'nothing can be done' [75]. Effective low vision rehabilita-
tion [122] and self-management training [130] have been
shown to assuage poor psychological well-being.
Although promising treatments are being developed,
findings about their impact on PROs are limited and we
have yet to hear of any treatment demonstrating benefits
to QoL using a genuine measure of QoL. It is hoped that
future trials will go beyond measuring visual function and
will include recently developed individualised measures
of QoL [42,44]. Given that there is no cure available for
anyone with MD and treatment to stabilise the condition
is limited to a small proportion of people with wet MD,
there is an urgent need to find other ways to curtail the
damage to QoL caused by MD.
A greater public awareness of MD and the consequences
of developing the condition are important. At present, lev-
els of awareness are strikingly low [147], with the highest,
30%, in the USA. In some countries with a prevalence of
MD comparable with the USA (e.g. Netherlands, Spain,
Italy) fewer than 10% of the population are aware of the
condition [147]. Increased awareness would lead to peo-
ple consulting health professionals earlier and being diag-
nosed with MD in time for any treatment that may be
appropriate to be effective in preserving vision. Evidence
suggests that the affective quality of diagnostic consulta-
tions can have a long-term impact on patients' well-being
(Mitchell, 2003). Good provision of information about
MD, about its consequences and ways in which patients
can monitor their vision and prevent unnecessary damagePage 14 of 20
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as the AMD Alliance and the UK MD Society and about
other organisations involved in helping visually impaired
people may improve patient satisfaction with their experi-
ence of diagnosis and may improve their long-term well-
being. Effective support and referral to other services as
needed is important for well-being. The widespread provi-
sion of effective rehabilitation services is essential for the
reduction of mental health problems which may develop
into clinical depression. Rehabilitation treatment needs to
be given as soon as possible and be designed to suit indi-
vidual needs [12]. Evaluation of MD patients' experiences
of services provided using purpose-designed instruments
such as the MacSSQ [89] will identify deficiencies and
enable targeted improvements to be made to the services
provided. Use of an appropriate QoL measure, such as the
MacDQoL will inform clinicians about the impact of MD
on individuals' QoL and help in identifying priorities in
the planning of rehabilitation programmes. Professional
psychological or psychiatric support should be offered
when needed. Well-being measures such as the W-BQ12
[15], a measure that has been evaluated for use with peo-
ple with MD, can be valuable in screening for unusually
high levels of depression and anxiety.
The use of QoL, well-being and vision function measures
in assessing the value of changes to the services offered to
people with MD will help to ensure that management of
this group of patients is effective. Slakter and Stur [12]
asserted that, ideally, different trials should use the same
measures to enable comparison of the effects. The evi-
dence cited in this review attests to the confusion that
arises out of using a multiplicity of measures, some of
which are insensitive and many of which are used inap-
propriately. It would be premature to recommend a spe-
cific set of measures for use in all trials, as some of the
instruments are relatively new, though it is clear that
health status measures such as the SF-36 and EQ5D are of
little relevance and utility values derived using TTO and
SG methods are misleading and best avoided. A variety of
visual function measures are available, with the NEI-VFQ
[38] being well established as a useful measure of visual
function in MD and commonly used in clinical trials
[24,28,142]. There is considerable evidence for the value
of the W-BQ12 measure of well-being (e.g [148-150]),
now psychometrically evaluated for people with MD [15].
There is growing evidence for the usefulness of the rela-
tively recent MacDQoL measure of the impact of MD on
quality of life which was developed specifically for people
with MD [42,44,151]. Such measures of well-being and
quality of life are urgently needed in clinical trials in addi-
tion to measures of visual function in a context of contin-
uing evaluation of their sensitivity to change in response
to treatments and rehabilitation for MD.
Data from the MDSQ [75] indicate that, before diagnosis
with MD, many older people lead active and fulfilling
lives, enjoying good quality of life and contributing to the
quality of life of others. There are promising early indica-
tions that heroic medical and surgical interventions may
prevent or even reverse the effects of MD for the small pro-
portion of patients affected by specific forms of wet MD.
These developments are very welcome. Nevertheless, we
cannot wait for a cure for MD to restore good quality of
life to all people with MD. Solutions to many of the prob-
lems highlighted in this report, such as improved empa-
thy in diagnostic consultations, provision of good
information, support and advice on self-help, would cost
little or nothing to implement. The potential to improve
the QoL of all people with MD exists, despite there being
no cure, if there is the will to invest in rehabilitation,
including low vision aid provision and training and in
ongoing support. Urgent action is needed worldwide to:
• increase public awareness
• improve training for health professionals in communi-
cation skills and use and interpretation of PRO measures
• increase the provision of support, rehabilitation and
LVA services
• evaluate services provided with audit which includes
PRO measurement
• increase use of appropriate QoL measures as well as
other suitable PRO measures in clinical trials of new treat-
ments
• increase funding for:
 research
 implementation of research findings
 continuing evaluation of the impact of diagnosis and
service provision on visual function, well-being, satisfac-
tion and quality of life of people with MD
Conclusion
Macular degeneration has a profoundly negative effect on
people's lives. Much could be done to improve outcomes.
Increased awareness of MD and its effects is needed
together with efforts to improve the experience of those
who are diagnosed with MD, through better information
and support, improved facilities for rehabilitation and
continuing evaluation of interventions using measures of
quality of life, patient satisfaction and psychological well-
being as well as measures of vision. With the very real
promise of a rapid increase in the incidence of MD, actionPage 15 of 20
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ple with MD including the most important outcome of
all, their quality of life.
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